



NATIONAL AND KAPODISTRIAN
UNIVERSITY OF ATHENS - MEDICAL SCHOOL



1ST CARDIOLOGY DEPARTMENT
NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS



GREEK NETWORK OF PRECISION MEDICINE IN CARDIOLOGY

GR | CARDIAC NET



UNIT OF INHERITED
AND RARE
CARDIOVASCULAR
DISEASES

Cardiac Amyloidosis & Genetic Cardiomyopathies

May, 3rd, 2023

"HIPPOKRATION" HOSPITAL
AMPHITHEATRE, 1ST FLOOR

May, 4th, 2023

B. & E. GOULANDRIS
FOUNDATION - MUSEUM,
PANGRATI

LIVE EVENT

FOR
YOUR
REGISTRATION
PRESS
HERE

FINAL PROGRAMME



Σας παρουσιάζουμε το **wtATTR-CM estimATTR**, ένα διαδικτυακό εργαλείο, που αναπτύχθηκε με βάση έναν αλγόριθμο τεχνητής νοημοσύνης / μηχανικής μάθησης (AI/ML). Στόχος του είναι η εκμάθηση του τρόπου με τον οποίο συνδυασμοί κλινικών σημείων σχετίζονται με αυτή τη νόσο, που έχει χαμηλά ποσοστά υποψίας και διάγνωσης.²⁻⁴

Η φυσικού τύπου σχετιζόμενη με την τρανσθυρετίνη αμυλοειδική μυοκαρδιοπάθεια (wtATTR-CM) είναι μια σπάνια και απειλητική για τη ζωή νόσος με χαμηλά ποσοστά υποψίας και διάγνωσης, η οποία συχνά διαφεύγει και δεν αναγνωρίζεται ως αιτία καρδιακής ανεπάρκειας.^{1,3,4} Μετά τη διάγνωση οι ασθενείς με φυσικού τύπου ATTR-CM, που δεν λαμβάνουν θεραπεία, έχουν διάμεση επιβίωση περίπου 3,5 έτη.⁵⁻⁷

Το **wtATTR-CM estimATTR** είναι ένα εύχρηστο εκπαιδευτικό εργαλείο, που αναπτύχθηκε με τη χρήση τεχνητής νοημοσύνης / μηχανικής μάθησης, για την εκτίμηση της πιθανότητας παρουσίας ATTR-CM φυσικού τύπου σε υποθετικούς ασθενείς με καρδιακή ανεπάρκεια. Το εργαλείο σας επιτρέπει να δοκιμάσετε διαφορετικούς συνδυασμούς κλινικών σημείων ενός υποθετικού ασθενούς, να δείτε ποιοι συνδυασμοί σχετίζονται με την φυσικού τύπου ATTR-CM και να σας βοηθήσουν να διακρίνετε την καρδιακή ανεπάρκεια εξαιτίας άλλων αιτιών.²

Το **wtATTR-CM estimATTR** προορίζεται αποκλειστικά για χρήση ως **εκπαιδευτικό εργαλείο** και δεν προορίζεται για χρήση σε κλινικό περιβάλλον για την υποψία ή τη διάγνωση της φυσικού τύπου ATTR-CM σε μεμονωμένους ασθενείς.

AI/ML: Artificial Intelligence/Machine Learning
wtATTR-CM: Wild-type transthyretin amyloid cardiomyopathy

estimattr.cardiacamyloidosis.gr



Βιβλιογραφία:

1. Witteles RM, Bokhari S, Darny T, et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. *JACC Heart Fail.* 2019;7(9):709-716.
2. Huda A., Castano A. et al , A machine learning model for identifying patients at risk for wild-type transthyretin amyloid cardiomyopathy ,2021, *Nature Communications* ,Volume 12, Article number: 2725
3. Mohammed SF, Mirzoyev SA, Edwards WD, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. *JACC Heart Fail.* 2014;2(2):113-122.
4. González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. *Eur Heart J.* 2015;36(38):2585- 2594.
5. Connors LH, Sam F, Skinner M, et al. Heart failure resulting from age-related cardiac amyloid disease associated with wildtype transthyretin: a prospective, observational cohort study. *Circulation.*2016;133(3):282-290.
6. Pinney JH, Whelan CJ, Petrie A, et al. Senile systemic amyloidosis: clinical features at presentation and outcome. *J Am Heart Assoc.* 2013;2(2):e000098.
7. Grogan M, Scott CG, Kyle RA, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. *J Am Coll Cardiol.* 2016;68:1014-1020.



INVITATION LETTER

The Scientific Meeting on **Cardiac Amyloidosis and Genetic Cardiomyopathies** aims to increase clinical and research awareness on the burden of cardiac amyloidosis and rare genetic cardiomyopathies to Public Health. Cardiac amyloidosis remains an underdiagnosed condition and approximately 25% of patients are dying from the disease within two years after the diagnosis. However, today, there are impressive developments in the therapeutic field permitting the stabilization of the disease and even the complete cure.

We are confident that the Meeting will be a unique opportunity for exchanging ideas and networking in the field with eminent scientists from Greece and abroad.

The Meeting will take place at the B. & E. Goulandris Foundation - Museum in Athens on May 4th, 2023 and the workshop on May 3rd, 2023 at the Amphitheatre on the 1st floor of Hippokration Hospital. It is organized by the 1st Cardiology Department of the National and Kapodistrian University of Athens and the Unit of Inherited and Rare Cardiovascular Diseases, which has long tradition in the field, being the first historic Cardiomyopathies Unit in Greece with important clinical and research work. The Meeting is co-organized by the Greek Network for Precision Medicine in Cardiology.

We look forward to welcoming you


On behalf of the Organizing Committee

Professor **Charalambos Vlachopoulos**

*Professor of Cardiology
Director of the Unit of Inherited
and Rare Cardiovascular Diseases
National and Kapodistrian
University of Athens*

Professor **Konstantinos Tsioufis**

*Professor of Cardiology
Head of the
1st Cardiology Department
National and Kapodistrian
University of Athens*



Cardiac Amyloidosis & Genetic Cardiomyopathies

May, 3rd, 2023

“HIPPOKRATION” HOSPITAL
AMPHITHEATRE, 1st FLOOR


15:00-15:05	<p>Introduction K. Tsioufis, Ch. Vlachopoulos</p>										
15:05-16:00	<p>Workshop - Multimodality imaging of cardiomyopathies Moderators: C. Aggeli, N. Alexopoulos</p> <table border="1"> <tr> <td>Echo in the diagnostic work-up of cardiomyopathies</td> <td>E. Oikonomou</td> </tr> <tr> <td>CMR in the diagnostic work-up of cardiomyopathies</td> <td>S. Loizos</td> </tr> <tr> <td>Nuclear modalities (CT/PET/SPECT) in the diagnostic work-up of cardiomyopathies</td> <td>G. Benetos</td> </tr> <tr> <td>Choosing the right patient for the right test</td> <td>I. Dimitroglou</td> </tr> </table>	Echo in the diagnostic work-up of cardiomyopathies	E. Oikonomou	CMR in the diagnostic work-up of cardiomyopathies	S. Loizos	Nuclear modalities (CT/PET/SPECT) in the diagnostic work-up of cardiomyopathies	G. Benetos	Choosing the right patient for the right test	I. Dimitroglou		
Echo in the diagnostic work-up of cardiomyopathies	E. Oikonomou										
CMR in the diagnostic work-up of cardiomyopathies	S. Loizos										
Nuclear modalities (CT/PET/SPECT) in the diagnostic work-up of cardiomyopathies	G. Benetos										
Choosing the right patient for the right test	I. Dimitroglou										
16:00-17:00	<p>Clinical vignettes of cardiomyopathies: from the common to the rare ones Moderator: A. Antonopoulos, I. Dima Speakers: Th. Katsimichas, I. Solomou</p>										
17:00-18:45	<p>Bring your (cardiomyopathy) case Moderators: A. Antonopoulos, A. Kordalis, E. Prappa</p> <ul style="list-style-type: none"> • Case 1: S. Stampola • Case 2: I. Liatakis • Case 3: A. Katinioti • Case 4: M. Boutsikou • Case 5: A. Xanthopoulos • Case 6: D. Terentes • Case 7: N. Kouris 										
18:45-20:00	<p>Cardio-Genetics 101 Moderators: A. Miliou, Ch. Vlachopoulos</p> <table border="1"> <tr> <td>Core concepts in genetic testing: available tests and methods</td> <td>A. Miliou</td> </tr> <tr> <td>Classification of variant pathogenicity</td> <td>G. Vogiatzi</td> </tr> <tr> <td>Clinical interpretation of Variants of Unknown Significance (VUS)</td> <td>A. Xintarakou</td> </tr> <tr> <td>Genetics in channelopathies</td> <td>N. Ioakeimidis</td> </tr> <tr> <td>Genetics in aortopathies</td> <td>A. Frogoudaki</td> </tr> </table>	Core concepts in genetic testing: available tests and methods	A. Miliou	Classification of variant pathogenicity	G. Vogiatzi	Clinical interpretation of Variants of Unknown Significance (VUS)	A. Xintarakou	Genetics in channelopathies	N. Ioakeimidis	Genetics in aortopathies	A. Frogoudaki
Core concepts in genetic testing: available tests and methods	A. Miliou										
Classification of variant pathogenicity	G. Vogiatzi										
Clinical interpretation of Variants of Unknown Significance (VUS)	A. Xintarakou										
Genetics in channelopathies	N. Ioakeimidis										
Genetics in aortopathies	A. Frogoudaki										



May, 4th, 2023

B. & E. GOULANDRIS FOUNDATION
MUSEUM, PANGRATI

09:00-09:05	Introduction K. Tsioufis, Ch. Vlachopoulos
09:05-10:45	HCM: established knowledge and new discoveries Moderators: G. Efthimiadis, G. Lazaros Early signs of HCM in sports preparticipation screening: what one should not miss M. Papadakis Beyond the HCM risk score for decision-making: risk modifiers A. Kasiakogias Septal reduction therapies for HOCM: alcohol vs. scalpel A. Rigopoulos Septal ablation: A success story S. Vaina Myosin Inhibitors: a paradigm shift in HOCM management? A. Naka Genetic cure for hypertrophic cardiomyopathy: Hype or reality? P. Makrythanasis Discussion
10:45-12:00	Common HCM phenocopies in clinical practice: made simple Moderator: A. Anastasakis Dare to think rare – the spectrum of Fabry cardiomyopathy M. Touloupaki Managing patients with late onset Pompe disease: tips and challenges G.K. Papadimas Danon cardiomyopathy: suspecting and treating a rare entity E. Papatheodorou Novel methods of genetic testing in inherited disease M. Tzeti Discussion



Cardiac Amyloidosis & Genetic Cardiomyopathies

May, 4th, 2023

B. & E. GOULANDRIS FOUNDATION
MUSEUM, PANGRATI

12:00-12:15	The Greek National Network of Precision Medicine in Cardiology Chairman: P. Vardas / Lecture: A. Anastasakis
12:15-12:30	COFFEE BREAK
12:30-13:45	DARE to live with a RARE disease in Greece: challenges and opportunities Moderators: K. Tsioufis, Ch. Vlachopoulos <ul style="list-style-type: none">• Living with a rare disease: the patients' voice• The high unmet need and Rare Diseases Community's asks: Rare Diseases Greece• Reimbursement of genetic testing in Greece: a call for action• Access to high-cost treatments for patients with a rare disease Discussants: D. Athanasiou, I. Kanakakis, P. Konstantoulakis, M. Pavlou, Ch. Spiliopoulou, C. Stefanadis, Th. Zaoutis
13:45-14:30	LUNCH BREAK
	DARE TO BARE the global burden of cardiac amyloidosis The connection between art and science Ch. Vlachopoulos
14:30-16:00	DARE to be AWARE Moderator: K. Tsioufis Screening For ATTR Amyloidosis: in the search of red flags A. Antonopoulos ATTR in TAVI: bystander or disease marker? K. Toutouzas The hives of amyloidosis in the Greek population E. Foukarakis Things to know on hereditary TTR amyloidosis G. Koutsis Taking care of families: screening of TTR variant carriers S. Maragkoudakis Discussion

Cardiac Amyloidosis & Genetic Cardiomyopathies



May, 4th, 2023

B. & E. GOULANDRIS FOUNDATION
MUSEUM, PANGRATI

16:00-17:30	STARE at the FLARE: how to diagnose	
	Moderators: C. Aggeli, I. Ikonomidis	
	Blood comes first: interpreting monoclonal gammopathy tests	E. Kastritis
	ECG in cardiac amyloidosis	G. Lazaros
	Imaging of amyloid fibers in the heart: strengths and pitfalls of each modality	
	• CMR /echo: I. Ninios • Nuclear bone scans: M. Koutelou	
Biopsy for amyloidosis diagnosis: when to use, what to target?	A. Briasoulis	
Molecular insights: the expert's view	I. Andreadou	
Discussion		
17:30-19:00	How to TAKE CARE	
	Moderators: G. Andrikopoulos, C. Chrysochoou	
	Therapeutic management of heart failure in cardiac amyloidosis: beyond targeted treatments	D. Farmakis
	Managing thromboembolism risk in patients with cardiac amyloidosis	E. Prappa
	Arrhythmia management in cardiac amyloidosis	D. Tsiachris
ICD for SCD prevention in amyloidosis?	S. Tzeis	
19:00-19:30	Satellite Lecture	
Chairpersons: K. Tsioufis, Ch. Vlachopoulos		
Accelerating the diagnosis and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM)	S. Perlini	
19:30-20:30	STARE at the GLARE: Discussion Forum on the challenges	
Moderators: E. Kastritis, I. Parisis		
I. Iakovou, L. Michalis, I. Papadopoulou, A. Pittas, I. Skoularigkis, K. Stamatelopoulos, Ch. Vlachopoulos		
20:30-20:40	Closing remarks	
K. Tsioufis, Ch. Vlachopoulos		

Ξαναγράφοντας το μέλλον τους: στοχεύοντας στη βελτίωση της νόσου στην πηγή της, με ONPATTRO® (patisiran)*¹⁻³



onpattro 
2 mg/mL concentrate for solution
for infusion patisiran

*Το ONPATTRO® (patisiran) ενδείκνυται για χρήση σε κληρονομική αμυλοείδωση που προκαλείται από τρανσθυρετίνη (αμυλοείδωση hATTR) σε ενήλικες ασθενείς με πολυνευροπάθεια σταδίου 1 ή σταδίου 2¹

hATTR, hereditary Transthyretin Amyloidosis

1. ONPATTRO® Περίληψη Χαρακτηριστικών του Προϊόντος
2. Adams D, et al. N Engl J Med. 2018;379(1):11-21
3. Adams D et al, Lancet Neurol. 2021;20:49-59

Περαιτέρω πληροφορίες διατίθενται από τη Γένεσις Φάρμα Α.Ε.

Για τις Συνταγογραφικές Πληροφορίες ανατρέξτε σε επόμενη σελίδα

**GENESIS**
pharma

Λ. Κηφισίας 274, 15232 Χαλάνδρι, Αθήνα
Τηλ.: 210 8771500, Fax: 210 6891918
e-mail: info@genesishpharma.com
www.genesishpharma.com


**Alnylam**
PHARMACEUTICALS

Alnylam Netherlands B.V.
Antonio Vivaldistraat 150
1083 HP Amsterdam
Netherlands

ΤΙΜΗ Ενδεικτική (N.T.): ONPATTRO C/S.SOL.IN 2MG/ML BTx1 VIALx 5 ML: 6.599,20€

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
αναφέρετε:
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για
ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

Cardiac Amyloidosis & Genetic Cardiomyopathies



ACKNOWLEDGEMENTS

The Chairmen and the Organizing Committee would like to express their sincere thanks to the following companies for their support:




ORGANIZING COMMITTEE

Presidents: K. Tsioufis, Ch. Vlachopoulos

Members: A. Antonopoulos, A. Kouroutzoglou
Th. Tsampras, A. Xintarakou

Cardiac Amyloidosis & Genetic Cardiomyopathies



PCO- CONGRESS SECRETARIAT

eventure
EVENT PLANNING & EDUCATION



11 Kolokotroni St, 14232 Nea Ionia, Greece
Tel.:+30 2160702929 , Mob.+30 6945454165
www.eventure.gr info@eventure.gr